{"id":3899,"date":"2025-09-22T12:31:40","date_gmt":"2025-09-22T10:31:40","guid":{"rendered":"https:\/\/www.esptcongress.org\/?page_id=3899"},"modified":"2025-09-22T15:19:33","modified_gmt":"2025-09-22T13:19:33","slug":"cecchin-erika","status":"publish","type":"page","link":"https:\/\/www.esptcongress.org\/index.php\/cecchin-erika\/","title":{"rendered":"Cecchin Erika"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;1\/4&#8243;]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">.shortcode-single-image-wrap.shortcode-single-image-da5823bcd45973c82e88e565b40d56bb.enable-bg-rollover .rollover i,\n.shortcode-single-image-wrap.shortcode-single-image-da5823bcd45973c82e88e565b40d56bb.enable-bg-rollover .rollover-video i {\n  background: -webkit-linear-gradient();\n  background: linear-gradient();\n}\n.shortcode-single-image-wrap.shortcode-single-image-da5823bcd45973c82e88e565b40d56bb .rollover-icon {\n  font-size: 32px;\n  color: #ffffff;\n  min-width: 44px;\n  min-height: 44px;\n  line-height: 44px;\n  border-radius: 100px;\n  border-style: solid;\n  border-width: 0px;\n}\n.dt-icon-bg-on.shortcode-single-image-wrap.shortcode-single-image-da5823bcd45973c82e88e565b40d56bb .rollover-icon {\n  background: rgba(255,255,255,0.3);\n  box-shadow: none;\n}<\/style><div class=\"shortcode-single-image-wrap shortcode-single-image-da5823bcd45973c82e88e565b40d56bb alignnone  vc_custom_1758537043060 enable-bg-rollover dt-icon-bg-off\" ><div class=\"shortcode-single-image\"><div class=\"fancy-media-wrap  layzr-bg\" style=\"\"><img fetchpriority=\"high\" decoding=\"async\" class=\"preload-me lazy-load aspect\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D&#39;http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg&#39;%20viewBox%3D&#39;0%200%20500%20500&#39;%2F%3E\" data-src=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Cecchin_foto-scaled-500x500.jpg\" data-srcset=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Cecchin_foto-scaled-500x500.jpg 500w, https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Cecchin_foto-scaled-1000x1000.jpg 1000w\" loading=\"eager\" sizes=\"(max-width: 500px) 100vw, 500px\" width=\"500\" height=\"500\"  data-dt-location=\"https:\/\/www.esptcongress.org\/index.php\/speakers\/cecchin_erika\/\" style=\"--ratio: 500 \/ 500;\" alt=\"\" \/><\/div><\/div><\/div><div class=\"standard-arrow list-divider bullet-top\"><ul>\n<li>Erika Cecchin, PharmD, PhD<\/li>\n<\/ul>\n<\/div>[\/vc_column][vc_column width=&#8221;3\/4&#8243;]<div id=\"ultimate-heading-969069f2fb3333ca6\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-969069f2fb3333ca6 uvc-727 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-969069f2fb3333ca6 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;\">CV<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-969069f2fb3333ca6 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Erika Cecchin is a clinical pharmacologist and director of the Clinical and Experimental Pharmacology Unit at the Oncology Reference Center (CRO) in Aviano, IRCCS, Italy. She is a member of the Academic Council of the Doctoral School of Biomedical Sciences and Biotechnology at the University of Udine and of the Academic Council of the School of Specialization in Clinical Pharmacology and Toxicology at the University of Trieste. She teaches pharmacology at the Universities of Trieste and Padua. She holds positions on the executive committee and as a scientific advisor for working groups of various international associations in the field of pharmacogenomics and therapeutic drug monitoring, such as ESPT (European Society of Pharmacogenomics and Personalized Medicine); IATDMCT (International Association of TDM and Clinical Toxicology); IUPHAR (International Union of Pharmacology) and national organizations such as the Italian Society of Pharmacology (SIF). Her research aims to study the use of pharmacogenetics and therapeutic drug monitoring to improve the safety and appropriateness of cancer treatments. A specific focus of her research is to define the contribution of rare germline variants in drug-related genes, currently not adopted in clinical practice, in predicting chemotherapy-related toxicity in cancer patients.<\/div><\/div><div id=\"ultimate-heading-14669f2fb3333ce7\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-14669f2fb3333ce7 uvc-7077 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-14669f2fb3333ce7 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;margin-top:50px;\">ABSTRACT<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-14669f2fb3333ce7 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\"><strong>Title: <\/strong>\u00a0<strong>Clinical benefit and utility of DPYD and UGT1A1 testing in gastrointestinal cancer: beyond single-gene targeted genotyping<\/strong><strong>.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>More than 21% of admissions to an oncology service are related to the management of adverse drug reactions. Germline genetic polymorphisms can identify patients at risk of toxicity. We recently demonstrated for the first time, that dose reductions of fluoropyrimidines (FP) and irinotecan (IRI) induced by DPYD and UGT1A1 genotyping in gastrointestinal cancer patients allowed patients to complete their course of treatment, with improved intensity of care. The development of the DPYD test in Europe is a successful example of clinical implementation of a pharmacogenetic test. Regulatory agencies now recommend pre-treatment genotyping for DPYD in Europe, and this was a key step in this process. Most oncology patients enrolled in Italy under PREPARE for FP-based prescribing received at least a second prescription managed by an oncologist with PGx guidelines available (at 18 months). This would encourage moving from a single drug-gene interaction analysis to a panel approach to increase cost-effectiveness and improve patient management. Moreover, the complexity of the genetics of DPYDs encourages the study of rare variants and the application of NGS techniques. Germline genetic variant burden determined by NGS could be a new pharmacogenetic marker to be further studied in the future.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u00a0<\/strong><\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3899","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/comments?post=3899"}],"version-history":[{"count":5,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3899\/revisions"}],"predecessor-version":[{"id":3948,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3899\/revisions\/3948"}],"wp:attachment":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/media?parent=3899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}